Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals (VRTX) shares fell 2.14% to $540.26 on Thursday, underperforming competitors like AbbVie and Krystal Biotech while Arcturus Therapeutics rose. The decline ended a three-day winning streak and left the stock 2.43% below its 52-week high. Trading volume was below the 50-day average. This occurred during a broader market downturn where the S&P 500 and Dow Jones also declined.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) slid 2.14% to $540.26 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.87% to 7,641.16 and Dow Jones Industrial Average falling 1.32% to 52,759.21.
The stock's fall snapped a three-day winning streak.
Vertex Pharmaceuticals Inc. closed 2.43% below its 52-week high of $553.69, which the company achieved on August 19th.
The stock underperformed when compared to some of its competitors Thursday, as AbbVie Inc. (ABBV) fell 1.56% to $261.83, Krystal Biotech Inc. (KRYS) fell 1.84% to $337.02, and Arcturus Therapeutics Holdings Inc. (ARCT) rose 6.91% to $10.99.
Trading volume (1.1 M) remained 555,889 below its 50-day average volume of 1.6 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 20, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-20-26 1637ET